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A b s t r a c t
Considerable variation in the use and duration of antiplatelet medications during the perioperative and postoperative care of 
patients undergoing coronary artery bypass grafting (CABG) reflects the limited number of studies focused directly on these 
patients as well as the variation in the results reported. In this review we highlight the incidence and mechanisms of graft closure 
as well as the evidence in support of antiplatelet therapy that is balanced by the impact of antiplatelet therapy on the risk of 
bleeding to provide recommendations for the use of this therapy in patients undergoing CABG. Low-dose acetylsalicylic acid 
(ASA; ≤ 160 mg daily) reduces the incidence of perioperative myocardial infarction, acute renal injury, and mortality without 
increasing the risk of bleeding and so is recommended both before and after CABG. The use of dual antiplatelet therapy with 
ASA plus a P2Y12 antagonist adds a greater risk of bleeding. While additional studies are required, we can make the following 
recommendations: because of increased bleeding and mortality when patients are treated with clopidogrel preoperatively, 
CABG should be delayed for five days. Because of increased bleeding when patients are treated with ticagrelor preoperatively, 
CABG should be delayed for three days. Because of increased bleeding when patients are treated with prasugrel preopera-
tively, CABG should be delayed for seven days. For patients who had a coronary stent placed preoperatively or had an acute 
coronary syndrome preoperatively, resumption of therapy with their P2Y12 antagonist postoperatively for 12 months reduces 
the subsequent incidence of cardiovascular events.
Key words: coronary artery bypass grafting, antiplatelet therapy, acetylsalicylic acid, clopidogrel
Kardiol Pol 2018; 76, 6: 945–952
INTRODUCTION
Despite increased usage of percutaneous coronary inter-
vention (PCI) for the treatment of coronary artery disease 
(CAD), coronary artery bypass grafting (CABG) remains 
an effective and durable treatment for multi-vessel CAD. 
Current guidelines recommend at least 12 months of dual 
antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) 
and P2Y12 antagonist for patients with acute coronary syn-
drome (ACS) and at least six months of DAPT for patients 
with stable CAD, who undergo percutaneous revascu-
larisation. The perioperative and postoperative treatment 
with antiplatelet agents in patients undergoing surgical 
revascularisation has been less extensively studied, with 
varying results reported. Furthermore, there is considerable 
variation in the use and duration of antiplatelet medica-
tions after CABG. In this review we highlight the incidence 
and mechanisms of graft closure as well as the evidence 
in support of antiplatelet therapy that is balanced by the 
impact of antiplatelet therapy on the risk of bleeding to 
provide recommendations for the use of this therapy in 
patients undergoing CABG.
MECHANISMS OF BYPASS GRAFT FAILURE
An important limitation of CABG is saphenous vein graft (SVG) 
failure that is associated with recurrent angina, the need for 
repeated coronary revascularisation, myocardial infarction 
(MI), and death [1, 2]. The use of an internal thoracic artery 
graft has been associated with improved outcomes because 
of greater long-term patency [3]. At 10 years internal thoracic 
artery patency ranges from 85% to 91% [3, 4]. By contrast, 
failure of SVGs one year after surgery ranges from 10% to 25% 
[4, 5]. Between one to five years after CABG an additional 
5% to 10% of SVGs will close, and from six to 10 years after 
CABG an additional 20% to 25% of SVGs will fail [6]. Thus, 
at 10 years SVG patency rates are approximately 50%, and 
only half of these are free of atherosclerosis [7]. SVG failure 
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can be considered as occurring early (within one month after 
CABG), intermediate (within the first year), or late [8].
Early graft failure that occurs within one month is primar-
ily due to technical failure or thrombosis, most commonly 
at the site of anastomosis. Endothelial injury is a key trig-
ger for early graft failure because exposure of blood to the 
sub-endothelium promotes platelet adhesion and thrombo-
sis. Initial harvesting of the vein disrupts the vasa vasorum 
and adventitia and can cause endothelial injury because of 
hypoxia [9]. In addition, intraoperative assessment of graft 
integrity by high-pressure distension can induce endothelial 
injury [10, 11] and thereby expose the sub-endothelium to 
pro-inflammatory and pro-coagulant reactions, even before 
aortocoronary graft implantation. Implantation exposes the 
vein to arterial pressure increasing the venous diameter, caus-
ing turbulent blood flow and shear stress that can damage the 
endothelium layer [12].
Intermediate graft failure that occurs between one 
month and one year after CABG is caused primarily by 
progressive neointimal thickening that is both cellular and 
acellular. A primary inciting factor is the exposure of veins 
to arterial pressure, which is likely to affect all SVGs to some 
extent [13, 14]. Arterial blood flow damages the endothe-
lium, leading to the release of growth factors and cytokines 
as well as initiating adhesion and activation of platelets 
and macrophages. Smooth muscle cells migrate from the 
media and proliferate. The migrated smooth muscle cells 
release extracellular matrix that contributes to neointimal 
thickening [15]. Factors that contribute to smooth muscle 
cell proliferation include reduction in nitric oxide produced 
by the endothelium as well as release of prostaglandins and 
adenosine [15, 16]. Migration and proliferation of smooth 
muscle cells and fibroblasts as well as extracellular matrix 
deposition contribute to neointimal hyperplasia, which en-
croaches on the lumen and promotes late graft failure from 
atherosclerosis [17].
Late graft failure that occurs more than one year after 
CABG is primarily caused by progressive atherosclerosis. En-
dothelial injury and neointimal hyperplasia initiate this pro-
cess. SVG atherosclerosis differs from native coronary artery 
atheroma in that it tends to be more diffuse and concentric 
but less calcified [18]. SVG atherosclerosis occurs at two main 
sites: at the aortic anastomosis and in the main shaft of the 
graft. Shaft lesions have been associated with increased rates 
of death and MI because they exhibit a greater incidence of 
plaque rupture and no-reflow [18, 19].
In summary, SVG failure is an important limitation of 
CABG. Platelets play a key role in this process [20], which is 
initiated by endothelial injury. Techniques that limit endothe-
lial injury are pivotal to long-term SVG patency. In light of the 
central role of platelets to SVG failure, antiplatelet therapy 
would be expected to limit SVG failure.
ANTIPLATELET AGENTS IN CABG
Early small studies with ASA, dipyridamole, and warfarin did 
not demonstrate clear benefits of these agents in the preven-
tion of SVG failure. Chesebro et al. [21] compared the combi-
nation of ASA and dipyridamole with placebo in 407 patients 
undergoing CABG. Treatment was begun as early as 7 h after 
surgery. Coronary angiography performed at one-month 
follow-up showed that SVG patency was significantly greater 
in the antiplatelet therapy cohort (98% vs. 90%, p < 0.001). 
Longer-term follow-up in the same study showed a significant 
difference in patency favouring antiplatelet therapy (89% 
vs. 77%, p < 0.001), suggesting that ASA plus dipyridamole 
prevented late as well as early SVG failure [12]. The Veter-
ans Administration Cooperative Study compared the use of 
different antiplatelet regimens for one year in 772 patients 
undergoing CABG [22]. Regimens tested included ASA 325 mg 
daily, ASA 325 mg three times daily, ASA plus dipyridamole 
(325 mg and 75 mg, three times daily), sulfinpyrazone 
(267 mg three times daily), and placebo (three times daily). At 
60 days post-surgery, 555 patients (1781 grafts) had coronary 
angiography. Graft patency was as follows: ASA once daily 
93.5%, ASA three times daily 92.3%, ASA and dipyridamole 
three times daily 91.9%, sulfinpyrazone 90.2%, and placebo 
85.2% (all ASA regimens were superior to placebo, p < 0.05). 
These results established the role of ASA as beneficial in the 
prevention of SVG failure during the first year after CABG. In 
addition to its effect on graft patency, ASA reduces in-hospital 
mortality [22–24]. Recent meta-analyses have demonstrated 
that preoperative ASA reduces the risk of perioperative MI 
by 21% to 44% [25, 26]. In addition, mortality was reduced 
by 29% and acute kidney injury was reduced by 32% [26]. 
Accordingly, ASA is recommended before CABG in both 
European and American guidelines [27, 28].
DAPT with a P2Y12 antagonist plus ASA prevents car-
diovascular events after ACS and PCI. The most extensively 
studied agent is clopidogrel. Clopidogrel is a thienopyridine 
pro-drug that requires metabolism to its active form that binds 
irreversibly to the platelet P2Y12 receptor [29]. Treatment of pa-
tients with ACS with the combination of ASA plus clopidogrel 
reduces the incidence of subsequent cardiovascular events 
[30]. In patients who had CABG, there was a trend favouring 
ASA plus clopidogrel with a reduction in the primary outcome 
(14.5% vs. 16.2%, ASA plus clopidogrel vs. ASA alone). The 
benefit in patients treated with ASA plus clopidogrel was seen 
before CABG while patients were waiting for surgery, and no 
benefit was demonstrated for clopidogrel after CABG [31].
No large randomised controlled trials have assessed the 
effect of DAPT on SVG patency. Gao et al. [32] randomised 
249 patients to either clopidogrel 75 mg plus ASA 100 mg 
daily or ASA 100 mg alone starting within 48 h of surgery. SVG 
patency that was assessed by computed tomography angio-
graphy (CTA) in 90% of patients at three months demonstrated 
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a higher patency in the ASA plus clopidogrel group compared 
to ASA alone (91.6% vs. 85.7%, p = 0.04). The Clopidogrel 
After Surgery for Coronary Artery Disease (CASCADE) trial was 
a randomised, double-blind, placebo-controlled trial com-
paring ASA 162 mg alone with ASA 162 mg plus clopidogrel 
75 mg [33]. Graft patency was assessed in 113 patients at one 
year by coronary angiography combined with intravascular 
ultrasound. The combination of ASA plus clopidogrel did not 
significantly decrease the development of intimal hyperplasia 
or affect SVG patency (94.3% vs. 93.2%). Rafiq et al. [34] re-
ported a randomised trial comparing ASA plus clopidogrel with 
ASA alone in patients undergoing CABG, who were deemed 
hypercoagulable by thromboelastography. They found no 
difference in SVG patency rates at three months. Mannacio 
et al. [35] assessed the impact of ASA 100 mg plus clopi-
dogrel compared with ASA alone in 300 patients undergoing 
off-pump CABG and found that SVG failure assessed by CTA 
was reduced (7.4% vs. 13.1%, p = 0.04) by the combination 
of ASA plus clopidogrel. Based on these results, current guide-
lines recommend one year of DAPT after CABG in patients 
presenting with ACS or undergoing off-pump surgery [36].
Ticagrelor, a non-thienopyridine P2Y12 antagonist that 
binds reversibly to the P2Y12 receptor prevented cardiovas-
cular events better than clopidogrel when combined with 
ASA in patients with ACS [37]. Among patients who were 
treated with CABG in the Platelet Inhibition and Patients 
Outcomes (PLATO) trial, the use of ticagrelor compared to 
clopidogrel was associated with better clinical outcomes both 
in ACS patients with prior CABG and in those who underwent 
a redo CABG [38, 39]. The primary and unexpected finding 
of reduced cardiovascular and total mortality among patients 
who had CABG was directionally consistent but substantially 
greater (more than twofold) compared with that of the parent 
study [37, 38]. Notably, the mortality benefits with ticagrelor 
were confined to patients in whom their P2Y12 antagonist 
(ticagrelor or clopidogrel) was discontinued two to four days 
before surgery [38]. These results support the notion that a re-
versible P2Y12 antagonist may have beneficial effects related to 
the redistribution of ticagrelor to young platelets released after 
surgery [40, 41]. CABG is associated with the release of young 
platelets that are pro-thrombotic [41]. Outcomes in patients 
undergoing CABG in the PLATO trial suggest that modest 
P2Y12 antagonism with ticagrelor discontinued two to four 
days before surgery will decrease mortality. A retrospective 
analysis of the TRITON-TIMI 38 trial, in which a risk-adjusted 
assessment of patients who underwent CABG after present-
ing with ACS, demonstrated a significantly reduced all-cause 
mortality with prasugrel compared with clopidogrel (2.31% 
vs. 8.67%, p = 0.025) [42]. 
A small hypothesis-generating study demonstrated that 
initiation of ticagrelor after CABG may improve SVG patency 
[43]. A total of 70 patients were enrolled in the study and ran-
domised to ASA alone or ASA plus ticagrelor 90 mg twice daily. 
Graft occlusion occurred in 7/25 (28.0%) patients on ASA plus 
ticagrelor and in 17/31 (48.3%) on ASA alone (p = 0.044). 
A recently published study from six tertiary hospitals in China 
compared ticagrelor plus ASA, ticagrelor alone, or ASA alone 
in 500 randomised patients undergoing elective CABG. Pa-
tients and physicians were not blinded to treatment allocation. 
The primary outcome was SVG patency assessed one year 
after CABG by either CTA or coronary angiography. Among 
the 500 randomised patients (mean age 63.6 years; 91 women 
[18.2%]), 461 (92.2%) completed the trial. SVG patency rates 
one year post-CABG were 88.7% (432 of 487 vein grafts) 
with ticagrelor plus ASA, 82.8% (404 of 488 vein grafts) with 
ticagrelor alone, and 76.5% (371 of 485 vein grafts) with ASA 
alone. The difference between ticagrelor plus ASA compared 
with ASA alone was significant (12.2%, 95% confidence in-
terval [CI] 5.2%–19.2%, p < 0.001), whereas the difference 
between ticagrelor alone compared with ASA alone was not 
significant (6.3%, 95% CI 1.1%–13.7%, p = 0.10). Five major 
bleeding episodes occurred during one year of follow-up 
(three with ticagrelor + ASA; two with ticagrelor alone). This 
evidence suggests that the combination of ticagrelor and 
ASA increased graft patency after one year [44]. In summary, 
a series of smaller trials suggest that the use of ticagrelor may 
reduce the incidence of SVG failure. Fortunately, two larger 
trials are actively recruiting patients to assess the impact of 
ticagrelor on SVG patency [45, 46].
BLEEDING, TRANSFUSION,  
AND ANTIPLATELET AGENTS IN CABG
Bleeding and the transfusion of blood products in patients 
undergoing CABG have been independently associated with 
an incrementally greater risk of death in direct proportion to 
the number of units transfused [47–50]. The adverse con-
sequences of bleeding that contribute to mortality include 
end-organ hypoperfusion that can lead to multiple organ 
dysfunction syndrome [50]. Transfusion of blood products is 
associated with haemolytic and non-haemolytic reactions, 
transmission of infectious diseases, transfusion-related acute 
lung injury, and transfusion-associated circulatory overload 
[48]. Because any antiplatelet therapy can be expected to 
increase the risk of bleeding, the choice to administer anti-
platelet therapy before surgery needs to balance the risks of 
bleeding with potential benefits.
A recent meta-analysis demonstrated that preoperative 
use of ASA was associated with an increased transfusion of 
blood products that was confined to higher doses of ASA 
because the use of low-dose ASA (≤ 160 mg/day) was not 
associated with an increase in transfusion [26]. Reoperation 
for bleeding was not increased by the preoperative use of 
ASA, but chest tube output was greater in patients receiving 
ASA preoperatively. Thus, the beneficial effects of ASA in the 
reduction of perioperative MI and the reduction in acute 
kidney injury are not offset by greater transfusion of blood 
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products or reoperation for bleeding when low-dose ASA is 
used. Consistent with these observations, mortality is reduced 
when low-dose ASA is used preoperatively.
While low-dose ASA does not appear to increase substan-
tially the risk of bleeding, DAPT has been consistently associ-
ated with a greater risk of bleeding. Because the newer agents, 
ticagrelor and prasugrel, are more powerful P2Y12 antagonists, 
and because ticagrelor binds reversibly to the P2Y12 recep-
tor while clopidogrel and prasugrel bind irreversibly, each of 
these agents must be considered individually. Furthermore, the 
antiplatelet effects of these agents will be affected substantially 
by the duration of time between the last dose of P2Y12 and 
the performance of CABG.
Among patients treated preoperatively with ASA plus 
clopidogrel, 5% had reoperation for bleeding, compared with 
1.9% reoperation rate in patients not treated with clopidogrel 
[51]. A report from a single-centre study as well as a national 
registry report from Sweden demonstrated that transfusion 
of blood products was greater in patients whose last dose of 
clopidogrel was < 120 h before surgery [52, 53]. Consistent 
with the greater incidence of bleeding, mortality was greater 
in patients treated with clopidogrel (3.9% vs. 2.5%, p < 0.001) 
[53]. Based on these results CABG should be performed more 
than 120 h after the last dose of clopidogrel unless there is 
a compelling clinical indication for earlier surgery.
Ticagrelor is indicated for the treatment of ACS, and an 
analysis of results in patients undergoing CABG noted a similar 
incidence of bleeding in patients randomised to either clopi-
dogrel or ticagrelor [38]. The offset of effects of ticagrelor are 
more rapid than those of clopidogrel [54]. The antiplatelet 
effects seen three days after discontinuation of ticagrelor are 
comparable with those seen five days after discontinuation 
of clopidogrel. Consistent with these observations, both 
a single-centre study as well as a national registry report from 
Sweden did not identify an increased risk of bleeding when 
ticagrelor was stopped 72 h before surgery [52, 53]. These 
results are consistent with the timing of mortality benefit seen 
in patients undergoing CABG and enrolled in the PLATO trial 
[38], and support a recommendation that CABG should be 
performed three to four days after the last dose of ticagrelor. 
There are limited trial data available for the preoperative 
use of prasugrel in patients undergoing CABG. Registry data 
suggest that patients treated with prasugrel have a longer delay 
from performance of catheterisation to CABG (median time 
114 h) and still exhibit a greater risk of bleeding [55]. A small 
(n = 143) single-centre registry study demonstrated that 
treatment with prasugrel was associated with more frequent 
surgical re-exploration for bleeding complications (8% vs. 1%, 
p = 0.03). Prasugrel is a thienopyridine P2Y12 antagonist that 
binds irreversibly to the receptor. The limited clinical data 
available suggest that discontinuation of prasugrel seven days 
before surgery is appropriate to limit the risk of bleeding.
ANTIPLATELET THERAPY AFTER CABG  
IN PATIENTS WITH CORONARY STENTS
Among patients who undergo CABG after placement of 
a coronary stent, consensus guidelines recommend that DAPT 
should be continued for the entire duration of therapy based 
on the type of stent, a class I recommendation [56]. The risk 
of stent thrombosis is influenced by the clinical syndrome 
as well as the type of stent. After ACS, one year of DAPT is 
recommended regardless of stent type. By contrast, a shorter 
duration of DAPT is acceptable when a bare metal stent is 
used for patients with stable CAD.
Stent thrombosis in bare metal stents is most likely to oc-
cur in the first few days to weeks after stent placement, and 
so the minimum duration of DAPT after PCI with a bare metal 
stent is one month. The risk of stent thrombosis in stable CAD 
after placement of a drug eluting stent is greatest in the first 
three to six months after implantation. Recent randomised 
controlled trials support a shorter duration of DAPT in patients 
with stable CAD [57, 58].
Palmerini et al. [59] identified 10 trials published be-
tween December 2011 and November 2014 that included 
31,666 randomly assigned patients. By frequentist pairwise 
meta-analysis, shorter DAPT was associated with significantly 
lower all-cause mortality compared with longer DAPT (hazard 
ratio [HR] 0.82, 95% CI 0.69–0.98, p = 0.02), with no signifi-
cant heterogeneity apparent across trials. The reduced mortal-
ity with shorter compared with longer DAPT was attributable 
to lower non-cardiac mortality (HR 0.67, 95% CI 0.51–0.89, 
p = 0.006), with similar cardiac mortality (HR 0.93, 95% CI 
0.73–1.17, p = 0.52). Shorter DAPT was associated with 
a lower risk of major bleeding, but a higher risk of MI and 
stent thrombosis [59]. This analysis is consistent with other 
such analyses that demonstrate decreased rates of bleeding 
with shorter DAPT duration that is offset by higher rates of 
stent thrombosis. Unfortunately, an important confounding 
variable is the continued evolution of technology with drug 
eluting stents. Fortunately, newer generation stents are as-
sociated with a lower rate of stent thrombosis and MI [60]. 
Nevertheless, a consistent finding is an increase in all-cause 
mortality and bleeding events associated with longer duration 
of DAPT [60, 61].
The balance between stent thrombosis and risk of 
bleeding has particular relevance when emergent CABG 
is performed in patients who were treated with coronary 
stent prior to surgery. Verma et al. [62] examined the effect 
of antiplatelet therapy on outcomes in patients after CABG. 
Their meta-analysis included nine randomised clinical trials 
(n = 4887) with up to one year of follow-up. Of these nine 
trials, seven compared clopidogrel plus ASA to ASA alone. 
Two of the trials reported on ACS patients who were treated 
with either ticagrelor (n = 1261) or prasugrel (n = 485) plus 
ASA compared with clopidogrel plus ASA. Post-operative 
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antiplatelet therapy was generally started when chest tube 
bleeding was no longer significant, typically within 24 to 48 h 
of surgery. There were no differences in all-cause mortality in 
clopidogrel plus ASA compared with ASA alone. By contrast, 
all-cause mortality was significantly lower when treatment 
with ticagrelor or prasugrel was compared with clopidogrel 
(risk ratio 0.49, 95% CI 0.33–0.71, p = 0.002; n = 1695; 
interaction p  <  0.01 compared to clopidogrel plus ASA 
vs. ASA trials). Although major bleeding was not significantly 
increased (relative risk 1.31, 95% CI 0.81–2.10, p  = 0.27; 
seven trials, n = 4500), heterogeneity was apparently related 
predominantly to greater bleeding associated with prasugrel 
attributable to CABG-related major bleeding (relative risk 
3.15, 95% CI 1.45–6.87, p = 0.004; one trial, n = 437).
The authors concluded that the benefit of treatment with 
DAPT after CABG is derived primarily from patients with ACS. 
Heterogeneity of trial design and medium sample sizes limit the 
analyses. Nevertheless, their results suggest that higher-intensity 
P2Y12 antagonist (prasugrel or ticagrelor) but not lower-intensity 
(clopidogrel) therapy was associated with a reduction in mortal-
ity among ACS patients treated with CABG [62].
SUMMARY/CLINICAL  
RECOMMENDATIONS (TABLE 1)
Because antiplatelet therapy reduces the risk of cardiovascular 
events in patients with CAD, it is not surprising that antiplatelet 
therapy reduces the risk of cardiovascular events in patients 
after CABG. Treatment with low-dose ASA reduces saphen-
ous vein graft failure in the first year after CABG. Moreover, 
it reduces MI and acute kidney injury without a meaningful 
increase in bleeding. These benefits combined with a reduc-
tion in mortality associated with low-dose ASA have led to 
consensus recommendation for the use of ASA both periop-
eratively and long-term after CABG.
The use of DAPT both perioperatively and long-term is 
less clearly defined. Based on available information we will 
provide clinical recommendations for each agent for both 
perioperative and long-term treatment.
Clopidogrel is a thienopyridine P2Y12 antagonist that binds 
irreversibly to the platelet. Attenuation of antiplatelet effects is 
mediated by the production and release of new platelets. Pa-
tients who have been treated with clopidogrel before CABG 
have a greater risk of bleeding and greater mortality when sur-
gery is performed less than five days (120 h) after the last dose. 
Based on these results, CABG should be delayed for five days 
after the last dose of clopidogrel unless earlier surgery is clinically 
indicated. In patients who have been treated preoperatively 
with a coronary stent and in patients who have had recent ACS, 
clopidogrel should be restarted after CABG and continued for 
one year to reduce the incidence of stent thrombosis and to 
reduce the risk of cardiovascular events.
Ticagrelor is a direct-acting P2Y12 antagonist that binds 
reversibly to platelets. Antiplatelet effects decline as the con-
centration of ticagrelor and its active metabolite decrease. 
Patients who have been treated preoperatively with ticagrelor 
exhibit greater bleeding when CABG is performed less than 
72 h after the last dose. Because clinical trial results demon-
strated a mortality benefit when CABG was performed three 
to four days after the last dose of ticagrelor, CABG should be 
performed more than three days (72 h) after the last dose of 
ticagrelor and consideration should be given to performing 
CABG from three to four days after the last dose of ticagrelor 
unless earlier surgery is clinically indicated. For patients who 
had a coronary stent placed preoperatively and those who 
had recent ACS, ticagrelor should be resumed postoperatively 
and continued for 12 months.
Prasugrel is a thienopyridine P2Y12 antagonist that binds 
irreversibly to the platelet. Antiplatelet effects decrease as new 
platelets are produced. Prasugrel is a powerful P2Y12 antago-
nist that has been associated with a substantially greater risk of 
bleeding. The limited clinical information available supports 
a seven-day delay of CABG after the last dose of prasugrel 
unless earlier surgery is clinically indicated. Similar to the other 
agents, preoperative placement of coronary stents and recent 
ACS should prompt re-initiation of therapy postoperatively to 
complete a one-year course.
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Table 1. Recommendations for antiplatelet therapy in patients undergoing CABG
Antiplatelet agent Days between last dose and 
CABG
Duration of treatment after 
CABG when preoperative ACS
Duration of treatment after 
CABG when preoperative  
stent for stable CAD
Acetylsalicylic acid 0 Long-term Long-term
Clopidogrel 5 1 year 6 months
Ticagrelor 3 1 year 6 months
Prasugrel 7 1 year 6 months
ACS — acute coronary syndrome; CABG — coronary artery bypass grafting; CAD — coronary artery disease
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